Table 1.
Demographic characteristics, co-morbidities and symptoms of all eligible patients and in the cohort of patients having filled the medical questionnaire by type of PCR results (positive, negative, untested)
| All eligible patients (n = 43 103) | Eligible patients with a completed medical questionnaire (n = 29 104) | Medical questionnaire and positive PCR (n = 7320) | Medical questionnaire and negative PCR (n = 5281) | Medical questionnaire and no PCR result (n = 16 503) |
|
|---|---|---|---|---|---|
| General characteristics | |||||
| Age, mean (SD) | 42.9 ± 14.3 | 43.0 ± 14.0 | 43.0 ± 13.9 | 43.1 ± 14.3 | 42.9 ± 13.9 |
| Women | 26 668 (61.9%) | 18 329 (63.0%) | 5006 (68.5%) | 3440 (65.2%) | 9883 (59.9%) |
| Male | 16 385 (38.1%) | 10 743 (37.0%) | 2301 (31.5%) | 1835 (34.8%) | 6607 (40.1%) |
| Time to registration in Covidom | |||||
| After symptom onset, days, median (Q1–Q3) | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 5.0 (3.0–8.0) | 4.0 (2.0–7.0) | 4.0 (2.0–7.0) |
| After physician referral, days, median (Q1–Q3) | 0.0 (0.0–1.0) | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 0.0 (0.0–1.0) | 0.0 (0.0–0.0) |
| High-risk profile | 17 160 (39.8%) | 11 521 (39.6%) | 2710 (37.0%) | 2406 (45.6%) | 6405 (38.8%) |
| Mode of inclusion | |||||
| GP | 23 087 (53.6%) | 16 115 (55.4%) | 1781 (24.3%) | 2921 (55.3%) | 11 413 (69.2%) |
| Hospital | 11 977 (27.8%) | 8053 (27.7%) | 4475 (61.1%) | 1763 (33.4%) | 1815 (11.0%) |
| EMS | 8039 (18.7%) | 4936 (17.0%) | 1064 (14.5%) | 597 (11.3%) | 3275 (19.8%) |
| Socio-economic indicators | |||||
| District median income in euros, median (Q1–Q3) | 24 110.0 (20 320.0–27 990.0) | 24 110.0 (20 320.0–27 990.0) | 23 160.0 (19 720.0–27 700.0) | 24 110.0 (20 320.0–28 180.0) | 24 110.0 (20 320.0–28 180.0) |
| Lowest income districts (Q1) | 11 718 (27.5%) | 7759 (27.0%) | 2286 (31.7%) | 1357 (26.0%) | 4116 (25.3%) |
| Median income districts (Q2-Q3) | 20 313 (47.8%) | 13 862 (48.3%) | 3317 (46.0%) | 2535 (48.6%) | 8010 (49.2%) |
| Highest income districts (Q4) | 10 505 (24.7%) | 7103 (24.7%) | 1610 (22.3%) | 1322 (25.4%) | 4171 (25.6%) |
| Risk factors | |||||
| 18 ≤ Age ≤ 45 years | 25 455 (59.1%) | 17 049 (58.6%) | 4160 (56.9%) | 3096 (58.6%) | 9793 (59.4%) |
| 45 < Age ≤ 65 years | 14 626 (33.9%) | 10 204 (35.1%) | 2774 (37.9%) | 1806 (34.2%) | 5624 (34.1%) |
| Age > 65 years | 3016 (7.0%) | 1845 (6.3%) | 383 (5.2%) | 379 (7.2%) | 1083 (6.6%) |
| BMI (kg/m2), median (Q1–Q3) | 24.8 (22.1-28.4) | 25.3 (22.4-29.1) | 24.7 (21.9-28.4) | 24.7 (22.0-28.2) | |
| Healthy weight (BMI ≤25 kg/m2) | 14 621 (51.5%) | 3424 (47.9%) | 2700 (53.0%) | 8497 (52.6%) | |
| Overweight (BMI 25–30 kg/m2) | 8568 (30.2%) | 2185 (30.6%) | 1451 (28.5%) | 4932 (30.5%) | |
| Obesity (BMI >30 kg/m2) | 5195 (18.3%) | 1532 (21.5%) | 942 (18.5%) | 2721 (16.8%) | |
| Current tobacco use | 5103 (17.7%) | 790 (10.9%) | 1163 (22.5%) | 3150 (19.2%) | |
| Main co-morbidities | |||||
| Asthma | 3685 (12.8%) | 814 (11.2%) | 824 (16.0%) | 2047 (12.5%) | |
| Hypertension | 3546 (12.3%) | 978 (13.5%) | 706 (13.7%) | 1862 (11.4%) | |
| Diabetes | 1385 (4.8%) | 402 (5.6%) | 286 (5.5%) | 697 (4.2%) | |
| Heart failure | 557 (1.9%) | 118 (1.6%) | 138 (2.7%) | 301 (1.8%) | |
| Chronic obstructive pulmonary disease | 517 (1.8%) | 87 (1.2%) | 147 (2.8%) | 283 (1.7%) | |
| Coronary artery disease | 399 (1.4%) | 77 (1.1%) | 97 (1.9%) | 225 (1.4%) | |
| Cancer under treatment | 322 (1.1%) | 92 (1.3%) | 106 (2.1%) | 124 (0.8%) | |
| Chronic renal disease | 312 (1.1%) | 66 (0.9%) | 69 (1.3%) | 177 (1.1%) | |
| Multiple co-morbidities (>1) | 1881 (6.5%) | 465 (6.4%) | 459 (8.9%) | 957 (5.8%) | |
| None of the reported co-morbidities | 20 468 (71.1%) | 5180 (71.6%) | 3378 (65.5%) | 11 910 (72.6%) | |
| Symptoms | |||||
| General symptoms | |||||
| Fatigue | 25 014 (85.9%) | 6592 (90.1%) | 4330 (82.0%) | 14 092 (85.4%) | |
| Temperature ≥38.5°C | 14 124 (48.5%) | 4130 (56.4%) | 2160 (40.9%) | 7834 (47.5%) | |
| Shivers | 15 706 (54.0%) | 4162 (56.9%) | 2570 (48.7%) | 8974 (54.4%) | |
| Myalgia | 15 721 (54.0%) | 4443 (60.7%) | 2574 (48.7%) | 8704 (52.7%) | |
| Fatigue, shivers, or myalgia | 26 258 (90.2%) | 6819 (93.2%) | 4582 (86.8%) | 14 857 (90.0%) | |
| Respiratory symptoms | |||||
| Cough | 18 014 (61.9%) | 4910 (67.1%) | 2816 (53.3%) | 10 288 (62.3%) | |
| Shortness of breath | 14 358 (49.3%) | 3470 (47.4%) | 2606 (49.3%) | 8282 (50.2%) | |
| Chest pain | 7643 (26.4%) | 1587 (21.8%) | 1433 (27.5%) | 4623 (28.1%) | |
| Chest oppression | 7913 (27.2%) | 1713 (23.4%) | 1479 (28.0%) | 4721 (28.6%) | |
| Gastrointestinal symptoms | |||||
| Anorexia | 11 216 (38.5%) | 3528 (48.2%) | 1616 (30.6%) | 6072 (36.8%) | |
| Nausea/vomiting | 6478 (22.3%) | 1771 (24.2%) | 1292 (24.5%) | 3415 (20.7%) | |
| Diarrhoea | 10 483 (36.0%) | 2742 (37.5%) | 1848 (35.0%) | 5893 (35.7%) | |
| Neurological symptoms | |||||
| Anosmia | 9109 (31.3%) | 4039 (55.2%) | 644 (12.2%) | 4426 (26.8%) | |
| Ageusia | 9170 (31.5%) | 3859 (52.7%) | 760 (14.4%) | 4551 (27.6%) | |
| Cutaneous symptoms | |||||
| Rash | 2851 (9.8%) | 721 (9.8%) | 499 (9.4%) | 1631 (9.9%) | |
| Chilblains | 580 (2.0%) | 128 (1.8%) | 111 (2.1%) | 341 (2.1%) | |
| Conjunctivitis | 2222 (7.6%) | 530 (7.2%) | 408 (7.7%) | 1284 (7.8%) | |
| Diagnosis confirmation | |||||
| PCR Untested | 14 983 (54.3%) | 0 (0.0%) | 0 (0.0%) | 14 983 (100.0%) | |
| PCR Negative | 5281 (19.1%) | 0 (0.0%) | 5281 (100.0%) | 0 (0.0%) | |
| PCR Positive | 7320 (26.5%) | 7320 (100.0%) | 0 (0.0%) | 0 (0.0%) | |
Abbreviations: BMI, body mass index; EMS, emergency medical service; GP, general practitioner.
Values are number (percentage) unless stated otherwise.